

## LITERATURA

- Boz C, Ozakbas S, Terzi M, et al. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. *Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2023;44(6):2121-2129. <https://doi.org/10.1007/S10072-023-06608-Z>.
- Brown JW, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA*. 2019;321(2):175-187. <https://doi.org/10.1001/JAMA.2018.20588>.
- Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population-based cohort. *European Journal of Neurology*. 2008;15(9):916-921. <https://doi.org/10.1111/J.1468-1331.2008.02241.X>.
- Determining the Effectiveness of early Intensive Versus Escalation Approaches for RRMS – Full Text View – ClinicalTrials.gov. (n.d.). Retrieved April 24, 2022, from <https://clinicaltrials.gov/ct2/show/NCT03535298>.
- Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. *Annals of Clinical and Translational Neurology*. 2014;1(10):755-764. <https://doi.org/10.1002/ACN3.114>.
- Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules. *Multiple Sclerosis and Related Disorders*. 2020;44:102311. <https://doi.org/10.1016/J.MSARD.2020.102311>.
- Goncuoglu C, Tuncer A, Bayraktar-Ekincioglu A, et al. Factors associated with fingolimod rebound: A single center real-life experience. *Multiple Sclerosis and Related Disorders*. 2021;56:103278. <https://doi.org/10.1016/J.MSARD.2021.103278>.
- Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. *JAMA Neurology*. 2019;76(5):536-541. <https://doi.org/10.1001/JAMANEUROL.2018.4905>.
- He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *The Lancet. Neurology*. 2020;19(4):307-316. [https://doi.org/10.1016/S1474-4422\(20\)30067-3](https://doi.org/10.1016/S1474-4422(20)30067-3).
- Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. *The Lancet. Neurology*. 2017;16(11):925-933. [https://doi.org/10.1016/S1474-4422\(17\)-30282-X](https://doi.org/10.1016/S1474-4422(17)-30282-X).
- Hrnciarova T, Drahota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. *Multiple Sclerosis and Related Disorders*. 2023;76. <https://doi.org/10.1016/J.MSARD.2023.104803>.
- Kim T, Brinker A, Croteau D, et al. Immune-mediated colitis associated with ocrelizumab: a new safety risk. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. 2023;29(10):1275-1281. <https://doi.org/10.1177/13524585231195854>.
- Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: a nationwide cohort study. *American Journal of Epidemiology*. 2005;162(8):774-8. <https://doi.org/10.1093/aje/kwi280>.
- Vaněčková M, Horáková D. Role magnetické rezonance při detekci oportunních infekcí v souvislosti s léčbou roztroušené sklerózy. *Neurol. praxi*. 2016;17(6):377-383. <https://doi.org/10.36290/NEU.2016.080>.
- Prosperini L, Mancinelli CR, Solaro CM, et al. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. *Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics*. 2020;17(3):994-1004. <https://doi.org/10.1007/S13311-020-00847-0>.
- Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. *Neurology*. 2019;93(15):e1452-e1462. <https://doi.org/10.1212/WNL.00000000000008243>.
- Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. *Multiple Sclerosis (Houndmills, Basingstoke, England)*. 2012;18(2):143-152. <https://doi.org/10.1177/1352458511435105>.
- Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs. Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. *JAMA Neurology*. 2021;78(10):1197-1204. <https://doi.org/10.1001/JAMANEUROL.2021.2738>.
- Stastna D, Drahota J, Lauer M, et al. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia*. 2023. <https://doi.org/10.5507/BP.2023.015>.
- Štátná D, Menkyová I, Horáková D. Okrelizumab již od první ataky roztroušené sklerózy – milník v úhradových kritériích. *Neurol. praxi*. 2022;23(4):312-316. <https://doi.org/10.36290/NEU.2022.030>.
- Štátná D, Seňavová J, Andělová M, et al. Internal comorbidities and complications of multiple sclerosis therapy – don't be caught off guard! *Vnitřní Lekarství*. 2023;69(5):294-298. <https://doi.org/10.36290/VNL.2023.058>.
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial – Full Text View – ClinicalTrials.gov. (n.d.). Retrieved April 24, 2022. Available from <https://clinicaltrials.gov/ct2/show/NCT03500328>.
- Uher T, Krasensky J, Malpas C, et al. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. *Neurology(R) Neuroimmunology & Neuroinflammation*. 2021;8(3). <https://doi.org/10.1212/NXI.0000000000000979>.
- Vaněčková M, Martinková A, Tupý R, et al. The spectrum of MRI findings of progressive multifocal leukoencephalopathy in patients with multiple sclerosis in the Czech Republic. *Ceska a Slovenska Neurologie a Neurochirurgie*. 2019;82(4):381-390. <https://doi.org/10.14735/AMCSNN2019381>.
- Zhu C, Kalincik T, Horakova D, et al. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. *JAMA Neurology*. 2023;80(7):739-748. <https://doi.org/10.1001/JAMANEUROL.2023.1542>.

DATA Z KLINICKÝCH STUDIÍ A REÁLNÉ KLINICKÉ PRAXE LÉKU SPINRAZA™ PROKAŽUJÍ, ŽE MOŽNÉ JE VÍCE<sup>1, 2</sup>



IS POSSIBLE\*

Obrázky jsou inspirovány podobou skutečných lidí žijících se spinální svalovou atrofií a slouží pouze pro ilustraci.

Reference: 1. SPINRAZA™ Summary of Product Characteristics. 2. Coratti G, et al. *Orphanet J Rare Dis*. 2021;16:430.

SMA = spinální svalová atrofie.

\* Možné je více

ZKRÁCENOU INFORMACI O PŘÍPRAVKU NAJDETE NA STRANĚ 448.

 **SPINRAZA™**  
(nusinersen) 12 mg solution for injection

SPINRAZA™ POMÁHÁ PACIENTŮM DOSÁHNOUT VÍCE v porovnání s kontrolní skupinou a přirozeným průběhem onemocnění.<sup>1, 2, \*\*</sup>

\*\* Přípravek SPINRAZA™ prokázal v randomizovaných kontrolovaných studiích klinicky a statisticky významné zlepšení motorických funkcí v porovnání s kontrolní skupinou. V podpůrných studiích a studiích z reálné klinické praxe se presymptomatictí dětští i dospělí pacienti významně zlepšili v porovnání s přirozeným průběhem onemocnění. Jednotlivé výsledky se mohou lišit v závislosti na závažnosti onemocnění a délce léčby.<sup>1, 2</sup>

 **Biogen**

Biogen (Czech Republic) s.r.o., Na Pankráci 1683/127, Praha 4, 140 00  
tel.: +420 255 706 200, [www.biogen.com.cz](http://www.biogen.com.cz), Biogen-225014, říjen 2023